masitinib mesylate


( Last Updated : November 29, 2022)
Generic Name:
masitinib mesylate
Project Status:
Active
Therapeutic Area:
Amyotrophic lateral sclerosis (ALS)
Manufacturer:
AB Science SA
Brand Name:
Alsitek
Project Line:
Reimbursement Review
Project Number:
SR0766-000
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Masitinib mesylate film-coated tablets in combination with riluzole is indicated for treatment of adult patients with amyotrophic lateral sclerosis (ALS).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Alsitek (masitinib mesylate) in combination with riluzole is indicated for treatment of adult patients with amyotrophic lateral sclerosis (ALS)
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openSeptember 29, 2022
Call for patient/clinician input closedNovember 18, 2022
Clarification:

- Patient input submission received from ALS Action Canada

Submission receivedOctober 28, 2022
Submission acceptedNovember 15, 2022
Clarification:

- Submission was not accepted for review on 11 Nov 2022

Review initiatedNovember 16, 2022
Draft CADTH review report(s) provided to sponsor for commentFebruary 15, 2023
Deadline for sponsors commentsFebruary 27, 2023
CADTH review report(s) and responses to comments provided to sponsorApril 14, 2023
Expert committee meeting (initial)April 26, 2023
Draft recommendation issued to sponsorMay 08, 2023
To
May 10, 2023
Draft recommendation posted for stakeholder feedbackMay 18, 2023
End of feedback periodJune 02, 2023